Five PHD inhibitors (BAY-853934, JTZ-951, FG-4592, AKB-6548 and GSK1278863) have entered clinical trials, with the most advanced (FG-4592) being in Phase III trials to treat anemia in patients with chronic kidney disease23. This evidence concerns the gene PDC and anemia (phenotype).